Savara (SVRA) Stock Highlights

3.13 | +6.46%

2024-11-21 04:19:20

Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The companys lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).

Statistics

Range Today

2.94 3.18

Volume Today 6.09M

Range 1 Year

2.82 5.7

Volume 1 Year 307.37M

Range 3 Year

1.02 5.7

Volume 3 Year 447.85M

Range 10 Year

0.69 17.187

Volume 10 Year 1.17B

Highlights

Market Capitalization 653.47M (small)

Floating Shares 105.42M

Current Price 3.13

Price To Earnings -9.95

Price To Book 5.39

Earnings Per Share -0.41

Payout Ratio 0%

Performance

Latest +6.46%

1 Month -16.09%

3 Months -29.66%

6 Months -29.98%

1 Year -16.09%

3 Years +192.52%

5 Years +232.98%

10 Years -58.27%

Benchmarks

Market Capitalization

151 / 368

Gross Profits

0 / 278

Total Revenue

0 / 300

Total Rank

257 / 368

Free Cashflow

148 / 352

Performance 5 years

28 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.